Business Model StrengthThe diversified revenue streams from sales, licensing, and partnerships provide a robust business model, enhancing resilience against market fluctuations.

Market PositionSpecialization in cardiovascular and metabolic therapies positions ABIONYX Pharma in a niche market with potential for high demand and limited competition.

Moderate LeverageModerate leverage indicates financial discipline and the ability to manage debt, which supports long-term financial stability.

Bears Say

Revenue DeclineDeclining revenue suggests challenges in maintaining market share or product demand, which could impact long-term growth prospects.

Negative Profit MarginsSubstantial negative profit margins highlight operational inefficiencies and ongoing financial losses, threatening the company's sustainability.

Liquidity ConcernsPersistent negative cash flows suggest liquidity challenges, limiting the company's ability to invest in growth and manage financial obligations.

0RAG FAQ

What was ABIONYX Pharma SA’s price range in the past 12 months?

ABIONYX Pharma SA lowest share price was €1.16 and its highest was €5.29 in the past 12 months.

What is ABIONYX Pharma SA’s market cap?

ABIONYX Pharma SA’s market cap is €126.29M.

When is ABIONYX Pharma SA’s upcoming earnings report date?

ABIONYX Pharma SA’s upcoming earnings report date is Mar 12, 2026 which is in 22 days.

How were ABIONYX Pharma SA’s earnings last quarter?

ABIONYX Pharma SA released its earnings results on Sep 25, 2025. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.

Is ABIONYX Pharma SA overvalued?

According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ABIONYX Pharma SA pay dividends?

ABIONYX Pharma SA does not currently pay dividends.

What is ABIONYX Pharma SA’s EPS estimate?

ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ABIONYX Pharma SA have?

ABIONYX Pharma SA has 35,511,654 shares outstanding.

What happened to ABIONYX Pharma SA’s price movement after its last earnings report?

ABIONYX Pharma SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.641%.

Which hedge fund is a major shareholder of ABIONYX Pharma SA?

Currently, no hedge funds are holding shares in GB:0RAG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ABIONYX Pharma SA

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.